Health Secretary's New Authority to Override NICE Sparks Parliamentary Backlash

In a move that appears designed to consolidate ministerial control over pharmaceutical spending, Health Secretary Wes Streeting has been granted the statutory authority to unilaterally overrule the National Institute for Health and Care Excellence’s (NICE) recommendations regarding the price the NHS pays for individual medicines, a development announced earlier this week amid limited parliamentary consultation. The unprecedented delegation of decision‑making power has immediately provoked a formal rebuke from a cross‑party group of parliamentarians, of whom thirty‑one have signed a motion in the House of Commons expressly condemning the measure as a breach of established procedural safeguards and a potential infringement of statutory limits on ministerial discretion. Critics further argue that the arrangement, by sidelining NICE’s independent cost‑effectiveness analysis, risks creating a pricing arena favoured by large pharmaceutical corporations, who stand to benefit from weakened negotiating leverage and the erosion of transparent, evidence‑based pricing mechanisms that have traditionally underpinned NHS drug procurement.

While the government contends that the authority is intended to expedite patient access to innovative therapies, the timing of the legislation—coinciding with a broader push to accelerate market entry of high‑cost drugs—raises doubts about whether the policy is truly patient‑centred or merely a conduit for commercial interests to circumvent rigorous appraisal. Legal scholars have pointed out that the statutory framework governing NICE’s remit does not explicitly provide for ministerial override, thereby exposing the executive to potential judicial review on grounds of ultra‑vires action and undermining the principle of an independent evidentiary body that safeguards public health spending from political expediency.

The episode therefore illustrates a recurring pattern wherein successive health administrations, faced with mounting pressure to deliver cutting‑edge treatments, resort to ad hoc expansions of ministerial prerogative that sidestep established checks and balances, a practice that not only erodes parliamentary trust but also threatens to institutionalise a precedent whereby expert agencies are rendered subordinate to short‑term political calculations. Unless Parliament imposes clearer statutory limits and restores a robust role for NICE, the policy trajectory set by this latest power grab is likely to persist, entrenching an environment in which fiscal decisions about life‑saving medicines remain vulnerable to the whims of a single ministerial office rather than the disciplined scrutiny of an independent scientific authority.

Published: April 26, 2026